203 related articles for article (PubMed ID: 34593007)
1. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
[TBL] [Abstract][Full Text] [Related]
2. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Ros S; Flöter J; Kaymak I; Da Costa C; Houddane A; Dubuis S; Griffiths B; Mitter R; Walz S; Blake S; Behrens A; Brindle KM; Zamboni N; Rider MH; Schulze A
Oncogene; 2017 Jun; 36(23):3287-3299. PubMed ID: 28092678
[TBL] [Abstract][Full Text] [Related]
3. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
4. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Dasgupta S; Rajapakshe K; Zhu B; Nikolai BC; Yi P; Putluri N; Choi JM; Jung SY; Coarfa C; Westbrook TF; Zhang XH; Foulds CE; Tsai SY; Tsai MJ; O'Malley BW
Nature; 2018 Apr; 556(7700):249-254. PubMed ID: 29615789
[TBL] [Abstract][Full Text] [Related]
5. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
6. E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.
Zhang L; Liu Z; Dong Y; Kong L
Life Sci; 2021 Jul; 276():119412. PubMed ID: 33774025
[TBL] [Abstract][Full Text] [Related]
7. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
8. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
9. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
10. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
11. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
12. HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT.
Fang L; Zhang Y; Zang Y; Chai R; Zhong G; Li Z; Duan Z; Ren J; Xu Z
Carbohydr Polym; 2019 Nov; 223():115109. PubMed ID: 31427001
[TBL] [Abstract][Full Text] [Related]
13. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
14. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
15. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B
Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771
[TBL] [Abstract][Full Text] [Related]
16. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
17. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
[TBL] [Abstract][Full Text] [Related]
19. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Yan H; Zhang J; Lin Z
Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
[TBL] [Abstract][Full Text] [Related]
20. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
